Aeternum Health (AETN) EBITDA Margin (2010 - 2026)

Aeternum Health has disclosed EBITDA Margin across 10 years of filings, most recently posting 5289.78% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 530358.0% year-over-year to 5289.78%; the TTM figure through Mar 2026 stood at 997.52% (down 86360.0% YoY), while the FY2025 annual figure was 132.22%, up 52884.0% from the prior year.
• EBITDA Margin slipped to 5289.78% in Q1 2026, from 349.98% in the prior quarter.
• Over the last five years, EBITDA Margin for AETN reached as high as 13.81% in Q1 2025 and fell as low as 11134.79% in Q3 2023.
• The 5-year median for EBITDA Margin is 976.64% (2023), against an average of 2080.91%.
• The widest YoY moves for EBITDA Margin: up 86359 bps in 2023, down 1032519 bps in 2023.
• A 5-year view of EBITDA Margin shows it stood at 598.13% in 2022, then sank by 485 bps to 3500.46% in 2023, then soared by 72 bps to 991.7% in 2024, then surged by 65 bps to 349.98% in 2025, then tumbled by 1411 bps to 5289.78% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 5289.78%, 349.98%, and 1449.29% for Q1 2026, Q4 2025, and Q3 2025 respectively.